MARKET

ATXI

ATXI

Avenue
NASDAQ

Real-time Quotes | Nasdaq Last Sale

3.390
-0.020
-0.59%
Closed 19:11 11/30 EST
OPEN
3.460
PREV CLOSE
3.410
HIGH
3.480
LOW
3.350
VOLUME
119.88K
TURNOVER
--
52 WEEK HIGH
12.34
52 WEEK LOW
2.850
MARKET CAP
56.78M
P/E (TTM)
-5.8257
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
Read This Before Selling Avenue Therapeutics, Inc. (NASDAQ:ATXI) Shares
We often see insiders buying up shares in companies that perform well over the long term. Unfortunately, there are...
Simply Wall St. · 11/13 10:28
The Daily Biotech Pulse: Novartis Acquires Gene Therapy Company, Moderna's Japanese Vaccine Supply Deal
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)
Benzinga · 10/29 11:30
The Daily Biotech Pulse: Catabasis Halts Duchenne Muscular Dystrophy Study, Lilly's COVID-19 Trial Disappointment, Merck, Pfizer Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 26)
Benzinga · 10/27 12:24
The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22)
Benzinga · 10/23 11:26
The Daily Biotech Pulse: FDA Vaccine Committee Meeting, Roche In $350M Deal for COVID-19 Treatment, Edwards Lifesciences Reports Q3 Beat
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 21)
Benzinga · 10/22 11:52
The Daily Biotech Pulse: Prothena Progress In Parkinson's Disease Pipeline, Fast Track For Xeris, Biogen Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 20)
Benzinga · 10/21 12:04
The Week Ahead In Biotech: Spectrum Pharma FDA Decision, Biogen And Abbott Earnings, Cancer Conference
Biopharma stocks, which started the week on a firm footing, lost momentum mid-way through amid market-wide sell-off triggered by waning stimulus hopes.
Benzinga · 10/18 16:50
Biotech Stock Roundup: REGN, GILD's Coronavirus News & Other Pipeline Updates
Regeneron (REGN) and Gilead (GILD) continue to be in the spotlight on coronavirus-related updates.
Zacks · 10/14 14:10
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ATXI. Analyze the recent business situations of Avenue through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ATXI stock price target is 9.00 with a high estimate of 12.00 and a low estimate of 6.00.
EPS
Institutional Holdings
Institutions: 45
Institutional Holdings: 2.79M
% Owned: 16.65%
Shares Outstanding: 16.75M
TypeInstitutionsShares
Increased
12
366.65K
New
9
-102.17K
Decreased
13
132.96K
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+4.66%
Pharmaceuticals & Medical Research
+1.09%
Key Executives
Chairman/Director
Lindsay Rosenwald
President/Chief Executive Officer/Director
Lucy Lu
Chief Financial Officer/Secretary
Joseph Vazzano
Director
Jaideep Gogtay
Director
Garrett Ingram
Independent Director
Neil Herskowitz
Independent Director
Jay Kranzler
Independent Director
Thomas Moore
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About ATXI
Avenue Therapeutics, Inc. is a pharmaceutical company. The Company is focused on developing and commercializing its product principally for use in the acute/intensive care hospital setting. The Company’s product candidate is intravenous (IV) Tramadol, for the treatment of moderate to moderately severe post-operative pain. Tramadol, a synthetic dual-acting opioid, is a centrally acting analgesic with weak opioid agonist properties. It also works via the inhibition of serotonin and noradrenaline re-uptake and blocking nociceptive impulses at the spinal level. Its Oral tramadol is marketed in the United States for moderate to moderately severe pain in adults. Its Parenteral tramadol formulations include IV, intramuscular (IM), and subcutaneous (SC) formulations. Tramadol is marketed in the United States under the trade name Ultram immediate release tablet. Ultracet is a combination product containing tramadol and acetaminophen, is also marketed in the United States.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Avenue Therapeutics Inc stock information, including NASDAQ:ATXI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ATXI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ATXI stock methods without spending real money on the virtual paper trading platform.